<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876900</url>
  </required_header>
  <id_info>
    <org_study_id>HP-3070-GL-04</org_study_id>
    <nct_id>NCT02876900</nct_id>
  </id_info>
  <brief_title>Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.</brief_title>
  <acronym>HP-3070</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Noven Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo
      transdermal patch in subjects diagnosed with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, randomized, double-blind, placebo-controlled, in-patient, efficacy, and
      safety study to evaluate HP-3070 for the treatment of schizophrenia.

      This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo
      transdermal patch in subjects diagnosed with schizophrenia, who are in an acute exacerbation
      and to assess the impacts of covariates on asenapine exposure as delivered in a patch
      formulation, using a population-based approach.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate Efficacy and Safety of Asenapine Maleate Patches Compared With Placebo Patches in Subjects Diagnosed With Schizophrenia as Measured Using the Syndrome Scale (PANSS) Total Score: Change From Baseline to Week 6.</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate efficacy and safety of HP-3070 compared with placebo for the treatment of schizophrenia as evaluated by Positive and Negative Syndrome Scale (PANSS) total score.
The PANSS total score is the sum of all 30 items (7 positive items, 7 negative items, and 16 general psychopathology items). For each item, severity was rated on an anchored 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. If one or more items are missing at a given assessment, the total score is set to missing. Total score ranges from 30 to 210. Score indicates severity of the disease, i.e. low score = low severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate Efficacy and Safety of Asenapine Maleate Patches Compared With Placebo Patches in Subjects Diagnosed With Schizophrenia as Measured Using the Clinical Global Impression - Severity of Illness Scale: Change From Baseline to Week 6.</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate efficacy and safety of HP-3070 compared with placebo for the treatment of schizophrenia as evaluated by the Clinical Global Impression - Severity of Illness Scale.
The severity of illness for each participant was rated using the CGI-S. The rater or Investigator answered the following question: &quot;Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?&quot;. Response choices included: 0 = not assessed; 1 = normal, not at all ill, 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">617</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Low dose Asenapine maleate patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose asenapine maleate, transdermal patches will be compared against placebo patches.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose asenapine maleate patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose asenapine maleate, transdermal patches will be compared against placebo patches.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo transdermal patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Low dose or high dose asenapine maleate transdermal patch will be compared against placebo patches</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Asenapine maleate transdermal patch</intervention_name>
    <description>The study will evaluate low dose Asenapine maleate transdermal patch</description>
    <arm_group_label>Low dose Asenapine maleate patch</arm_group_label>
    <other_name>Transdermal patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Asenapine maleate transdermal patch</intervention_name>
    <description>The study will evaluate high dose Asenapine maleate transdermal patch</description>
    <arm_group_label>High dose asenapine maleate patch</arm_group_label>
    <other_name>Transdermal patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The study will evaluate placebo transdermal patch.</description>
    <arm_group_label>High dose asenapine maleate patch</arm_group_label>
    <arm_group_label>Low dose Asenapine maleate patch</arm_group_label>
    <arm_group_label>Placebo transdermal patch</arm_group_label>
    <other_name>Sham treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current diagnosis of schizophrenia.

          -  Subject has PANSS total score â‰¥80, AND score of 4 or more in at least 2 of the
             following PANSS items at Screening and at Baseline: conceptual disorganization
             delusions; hallucinatory behavior; unusual thought content.

          -  Subjects must be able to wear a transdermal patch for 24 hours.

        Exclusion Criteria:

          -  Subject has been diagnosed with schizophrenia less than 6 months prior to Screening
             Visit.

          -  Subject has received within 90 days of Screening Visit: electroconvulsive therapy;
             transcranial magnetic stimulation; vagal nerve stimulation; or other brain stimulation
             treatments

          -  Subject has experienced acute depressive symptoms within 30 days prior to Screening
             Visit that requires treatment with an antidepressant, as determined by the
             Investigator.

          -  Currently taking clozapine for the treatment of schizophrenia.

          -  Has hypothyroidism or hyperthyroidism.

          -  Subject is currently being treated with insulin for diabetes.

          -  Subject has epilepsy or history of seizures.

          -  Positive urine pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Harb, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Noven Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Noven Pharmaceuticals, Inc.</name>
      <address>
        <city>Jersey City</city>
        <state>New Jersey</state>
        <zip>07310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <results_first_submitted>February 28, 2020</results_first_submitted>
  <results_first_submitted_qc>March 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2020</results_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asenapine</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 20, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT02876900/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT02876900/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Asenapine Maleate Patch</title>
          <description>Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
Low Dose Asenapine maleate transdermal patch: The study will evaluate low dose Asenapine maleate transdermal patch.
Placebo: Evaluate Low Dose versus Placebo.</description>
        </group>
        <group group_id="P2">
          <title>High Dose Asenapine Maleate Patch</title>
          <description>High dose asenapine maleate, transdermal patches will be compared against placebo patches.
High Dose Asenapine maleate transdermal patch: The study will evaluate high dose Asenapine maleate transdermal patch
Placebo: Evaluate High Dose versus Placebo.</description>
        </group>
        <group group_id="P3">
          <title>Placebo Patch</title>
          <description>Placebo transdermal patch</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="206"/>
                <participants group_id="P3" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="158"/>
                <participants group_id="P3" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 616 subjects were randomized in the double-blind treatment period of the study and were included in the Intent-to-Treat (ITT) analysis set (206 patients in HP-3070 18.0 mg group, 204 patients in HP-3070 9.0 mg group, 206 patients in placebo group). One additional subject met exclusion criteria for the study but was not dosed (n=617).</population>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Asenapine Maleate Patch</title>
          <description>Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
Low Dose Asenapine maleate transdermal patch: The study will evaluate low dose Asenapine maleate transdermal patch
Placebo: The study will evaluate placebo transdermal patch.</description>
        </group>
        <group group_id="B2">
          <title>High Dose Asenapine Maleate Patch</title>
          <description>High dose asenapine maleate, transdermal patches will be compared against placebo patches.
High Dose Asenapine maleate transdermal patch: The study will evaluate high dose Asenapine maleate transdermal patch
Placebo: The study will evaluate placebo transdermal patch.</description>
        </group>
        <group group_id="B3">
          <title>Placebo Patch</title>
          <description>Placebo transdermal patch</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="204"/>
            <count group_id="B2" value="206"/>
            <count group_id="B3" value="206"/>
            <count group_id="B4" value="616"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="206"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="171"/>
                    <measurement group_id="B4" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="206"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="206"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="206"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="205"/>
                    <measurement group_id="B4" value="600"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>A total of 616 subjects were randomized in the study and were included in the ITT analysis set. For Race, a subject could select more than one race in the case report form.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="206"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="468"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="206"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="206"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="206"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="206"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="206"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="206"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.5" spread="9.08"/>
                    <measurement group_id="B2" value="171.8" spread="9.09"/>
                    <measurement group_id="B3" value="171.8" spread="9.16"/>
                    <measurement group_id="B4" value="172.0" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="206"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.591" spread="5.1151"/>
                    <measurement group_id="B2" value="26.240" spread="4.7834"/>
                    <measurement group_id="B3" value="25.925" spread="4.8602"/>
                    <measurement group_id="B4" value="26.251" spread="4.9205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PANSS total score</title>
          <population>Safety Analysis Set = 614 subj who received double-blind medication. PANSS total score is sum of all 30 items (7 positive items, 7 negative items &amp; 16 general psychopathology items). For each item, severity rated on an anchored 7-point scale; score of 1=absence of symptoms, score of 7=extremely severe symptoms. Total score ranges from 30 to 210.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="204"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;90</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=90</title>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluate Efficacy and Safety of Asenapine Maleate Patches Compared With Placebo Patches in Subjects Diagnosed With Schizophrenia as Measured Using the Syndrome Scale (PANSS) Total Score: Change From Baseline to Week 6.</title>
        <description>To evaluate efficacy and safety of HP-3070 compared with placebo for the treatment of schizophrenia as evaluated by Positive and Negative Syndrome Scale (PANSS) total score.
The PANSS total score is the sum of all 30 items (7 positive items, 7 negative items, and 16 general psychopathology items). For each item, severity was rated on an anchored 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. If one or more items are missing at a given assessment, the total score is set to missing. Total score ranges from 30 to 210. Score indicates severity of the disease, i.e. low score = low severity.</description>
        <time_frame>6 weeks</time_frame>
        <population>Results are from the full analysis set (FAS) which includes all randomized participants who had at least 1 patch of double-blind study medication applied and who have a baseline PANSS total score and at least 1 post baseline assessment of the primary efficacy measure (PANSS total score) and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Asenapine Maleate Patch</title>
            <description>Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
Low Dose Asenapine maleate transdermal patch: The study will evaluate low dose Asenapine maleate transdermal patch
Placebo: The study will evaluate placebo transdermal patch.</description>
          </group>
          <group group_id="O2">
            <title>High Dose Asenapine Maleate Patch</title>
            <description>High dose asenapine maleate, transdermal patches will be compared against placebo patches.
High Dose Asenapine maleate transdermal patch: The study will evaluate high dose Asenapine maleate transdermal patch
Placebo: The study will evaluate placebo transdermal patch.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Patch</title>
            <description>Placebo transdermal patch</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate Efficacy and Safety of Asenapine Maleate Patches Compared With Placebo Patches in Subjects Diagnosed With Schizophrenia as Measured Using the Syndrome Scale (PANSS) Total Score: Change From Baseline to Week 6.</title>
          <description>To evaluate efficacy and safety of HP-3070 compared with placebo for the treatment of schizophrenia as evaluated by Positive and Negative Syndrome Scale (PANSS) total score.
The PANSS total score is the sum of all 30 items (7 positive items, 7 negative items, and 16 general psychopathology items). For each item, severity was rated on an anchored 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. If one or more items are missing at a given assessment, the total score is set to missing. Total score ranges from 30 to 210. Score indicates severity of the disease, i.e. low score = low severity.</description>
          <population>Results are from the full analysis set (FAS) which includes all randomized participants who had at least 1 patch of double-blind study medication applied and who have a baseline PANSS total score and at least 1 post baseline assessment of the primary efficacy measure (PANSS total score) and completed the study.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.1" spread="1.158"/>
                    <measurement group_id="O2" value="-20.4" spread="1.162"/>
                    <measurement group_id="O3" value="-15.5" spread="1.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The mixed model for repeated measures includes treatment, country, visit, treatment by visit interaction, and baseline value as covariates, and participant as random effect. The correlation of repeated measures within a participant is estimated with an unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Assuming an effect size of 0.35 on the change in PANSS total score from baseline to Week 6 for the 2 pairwise comparisons between each active asenapine maleate transdermal patch treatment arm and placebo, the power for detecting a statistically significant HP-3070 advantage was approximately 0.90, having 204 evaluable participants per each treatment arm using a 2-sided alpha level of 0.025 for each comparison.</non_inferiority_desc>
            <p_value>0.003</p_value>
            <p_value_desc>Adjusted p-value was calculated according to the truncated Hochberg procedure with a truncation factor y=0.9. Adjustment for multiple comparisons uses a parallel gatekeeping procedure.</p_value_desc>
            <method>Mixed Model Repeated Measures Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-4.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.634</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.06</ci_lower_limit>
            <ci_upper_limit>-1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The mixed model for repeated measures includes treatment, country, visit, treatment by visit interaction, and baseline value as covariates, and participant as random effect. The correlation of repeated measures within a participant is estimated with an unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Assuming an effect size of 0.35 on the change in PANSS total score from baseline to Week 6 for the 2 pairwise comparisons between each active asenapine maleate transdermal patch treatment arm and placebo, the power for detecting a statistically significant HP-3070 advantage was approximately 0.90, having 204 evaluable participants per each treatment arm using a 2-sided alpha level of 0.025 for each comparison.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted p-value was calculated according to the truncated Hochberg procedure with a truncation factor y=0.9. Adjustment for multiple comparisons uses a parallel gatekeeping procedure.</p_value_desc>
            <method>Mixed Model Repeated Measures Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-6.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.81</ci_lower_limit>
            <ci_upper_limit>-3.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Efficacy and Safety of Asenapine Maleate Patches Compared With Placebo Patches in Subjects Diagnosed With Schizophrenia as Measured Using the Clinical Global Impression - Severity of Illness Scale: Change From Baseline to Week 6.</title>
        <description>To evaluate efficacy and safety of HP-3070 compared with placebo for the treatment of schizophrenia as evaluated by the Clinical Global Impression - Severity of Illness Scale.
The severity of illness for each participant was rated using the CGI-S. The rater or Investigator answered the following question: &quot;Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?&quot;. Response choices included: 0 = not assessed; 1 = normal, not at all ill, 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.</description>
        <time_frame>6 weeks</time_frame>
        <population>Results are from the full analysis set (FAS) which includes all randomized participants who had at least 1 patch of double-blind study medication applied and who have a baseline PANSS total score and at least 1 post baseline assessment of the primary efficacy measure (PANSS total score) and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Asenapine Maleate Patch</title>
            <description>Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
Low Dose Asenapine maleate transdermal patch: The study will evaluate low dose Asenapine maleate transdermal patch
Placebo: The study will evaluate placebo transdermal patch.</description>
          </group>
          <group group_id="O2">
            <title>High Dose Asenapine Maleate Patch</title>
            <description>High dose asenapine maleate, transdermal patches will be compared against placebo patches.
High Dose Asenapine maleate transdermal patch: The study will evaluate high dose Asenapine maleate transdermal patch
Placebo: The study will evaluate placebo transdermal patch.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Patch</title>
            <description>Placebo transdermal patch</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate Efficacy and Safety of Asenapine Maleate Patches Compared With Placebo Patches in Subjects Diagnosed With Schizophrenia as Measured Using the Clinical Global Impression - Severity of Illness Scale: Change From Baseline to Week 6.</title>
          <description>To evaluate efficacy and safety of HP-3070 compared with placebo for the treatment of schizophrenia as evaluated by the Clinical Global Impression - Severity of Illness Scale.
The severity of illness for each participant was rated using the CGI-S. The rater or Investigator answered the following question: &quot;Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?&quot;. Response choices included: 0 = not assessed; 1 = normal, not at all ill, 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.</description>
          <population>Results are from the full analysis set (FAS) which includes all randomized participants who had at least 1 patch of double-blind study medication applied and who have a baseline PANSS total score and at least 1 post baseline assessment of the primary efficacy measure (PANSS total score) and completed the study.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.90"/>
                    <measurement group_id="O2" value="-1.2" spread="0.96"/>
                    <measurement group_id="O3" value="-0.9" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The mixed model for repeated measures includes treatment, country, visit, treatment by visit interaction, and baseline value as covariates, and participant as random effect. The correlation of repeated measures within a participant is estimated with an unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted p-value was calculated according to the Hochberg procedure. Adjustment for multiple comparisons uses a parallel gatekeeping procedure.</p_value_desc>
            <method>Mixed Model Repeated Measures Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The mixed model for repeated measures includes treatment, country, visit, treatment by visit interaction, and baseline value as covariates, and participant as random effect. The correlation of repeated measures within a participant is estimated with an unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted p-value was calculated according to the Hochberg procedure. Adjustment for multiple comparisons uses a parallel gatekeeping procedure.</p_value_desc>
            <method>Mixed Model Repeated Measures Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.099</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From date of first dose of doubleblind (DB) study medication (Day 1) through the 30 day follow-up period, approximately 72 days.</time_frame>
      <desc>The safety analysis set included all participants who had at least 1 patch of double-blind study medication applied and who have at least 1 post dose safety measurement during the double-blind treatment period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Asenapine Maleate Patch</title>
          <description>Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
Low Dose Asenapine maleate transdermal patch: The study will evaluate low dose Asenapine maleate transdermal patch
Placebo: The study will evaluate placebo transdermal patch.</description>
        </group>
        <group group_id="E2">
          <title>High Dose Asenapine Maleate Patch</title>
          <description>High dose asenapine maleate, transdermal patches will be compared against placebo patches.
High Dose Asenapine maleate transdermal patch: The study will evaluate high dose Asenapine maleate transdermal patch
Placebo: The study will evaluate placebo transdermal patch.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo transdermal patch</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MeDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal ulcer hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MeDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="105" subjects_affected="19" subjects_at_risk="204"/>
                <counts group_id="E2" events="57" subjects_affected="20" subjects_at_risk="204"/>
                <counts group_id="E3" events="14" subjects_affected="3" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="204"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="204"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="204"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="204"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="204"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="204"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="204"/>
                <counts group_id="E3" events="28" subjects_affected="23" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="204"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E3" events="19" subjects_affected="13" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George Harb, MD, MPH - Executive Director, Clinical Development</name_or_title>
      <organization>Noven Pharmaceuticals</organization>
      <phone>1-551-233-2656</phone>
      <email>gharb@noven.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

